CBT-NPC is under clinical development by CHA Biotech and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CBT-NPC’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CBT-NPC overview
CBT-NPC is under development for the treatment of Parkinson's disease. CBT-NPC comprises of neuro progenitor cells. Adult stem cells potentially replace lost or support damaged brain cells due to their remarkable ability of differentiating into many cell types. They can provide both anti-inflammatory, regenerative functions, and immune-regulating properties, all of which could be neuroprotective.
CHA Biotech overview
CHA Biotech, formerly CHA Bio & Diostech, is a biotechnology company that develops new drugs by conducting basic research and clinical trials. The company offers services including cell therapeutics development, bio insurance, cord blood and stem cell banking solutions, cell therapeutic development services, integrated stem cell solutions, pre and post care services, among others. The company provides hospital information and technology management services across Japan. CHA Biotech is headquartered in Seongnam, Gyeonggido, South Korea.
For a complete picture of CBT-NPC’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
